Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

J. Gligorov, B. Ataseven, M. Verrill, M. De Laurentiis, K. H. Jung, H. A. Azim, N. Al-Sakaff, S. Lauer, M. Shing, X. Pivot, Dhurata Koroveshi, Kamel Bouzid, Monica Casalnuovo, Diana Cascallar, Ernesto Pablo Korbenfeld, Patricia Bastick, Jane Beith, Maree Colosimo, Michael Friedlander, Vinod GanjuMichael Green, Kevin Patterson, Andrew Redfern, Gary Richardson, Timur Ceric, Kecman Gordana, Carlos Augusto Beato, Marcela Ferrari, Roberto Hegg, Vanessa Helena, Gustavo Fernando Ismael, Alvaro Edson Lessa, Max Mano, Alessandra Morelle, Jose Alberto Nogueira, Konstanta Timcheva, Antoaneta Tomova, Maya Tsakova, Ani Zlatareva-Petrova, Jamil Asselah, Hazem Assi, Christine Brezden-Masley, Stephen Chia, Ori Freedman, Mohammed Harb, Anil Abraham Joy, Swati Kulkarni, Catherine Prady, Alejandro Andres Acevedo Gaete, Mohamed Idris, the SafeHer Study Group

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Aim To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721). Methods Patients received 600 mg fixed-dose H SC every 3 weeks for 18 cycles. The chemotherapy partner was at the investigators' discretion (H SC monotherapy was limited to ≤10% of the population). Data from the first H SC dose until 28 days (plus a 5-day window) after the last dose are presented. Results are descriptive. Results In the overall population, 2282/2573 patients (88.7%) experienced adverse events (AEs). Of the above, 128 (5.0%) patients experienced AEs leading to study drug discontinuation; 596 (23.2%) experienced grade ≥ 3 AEs and 326 (12.7%) experienced serious AEs. Grade ≥ 3 cardiac disorders were reported in 24 patients (0.9%), including congestive heart failure in eight (0.3%). As expected, the AE rates varied according to the timing of chemotherapy in both cohorts, with higher rates in concurrent versus sequential chemotherapy subgroups. In the concurrent chemotherapy subgroup, AEs were more common during the actual period of concurrent chemotherapy compared with the period when patients did not receive concurrent chemotherapy. Conclusion SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC. These primary analysis results are consistent with the known safety profile for intravenous H and H SC.

Original languageEnglish
Pages (from-to)237-246
Number of pages10
JournalEuropean Journal of Cancer
Volume82
DOIs
Publication statusPublished - Sep 1 2017

Keywords

  • Adjuvant
  • Breast cancer
  • HER2/neu
  • Herceptin
  • Subcutaneous
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. Together they form a unique fingerprint.

Cite this